Longeveron Shares Jumped Another 10% in Morning Trading

180
19
Favorite

Longeveron Shares Jumped Another 10% in Morning Trading

Tiger Newspress2022-04-01

Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.

Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.

The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.

Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.

The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.

“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.

In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

180

Report

Comment（19）

Gneiss
·2022-04-05
Great news!
Reply
1
Report
Mm101
·2022-04-04
Ff
Reply
1
Report
Fold Replies
- Mm101:
  Pp
  2022-04-04
  Reply
  Report
- Mm101:
  Gf
  2022-04-04
  Reply
  Report
- Mm101:
  Dd
  2022-04-04
  Reply
  Report
View more 2 comments
Wenikho
·2022-04-02
Ok
Reply
2
Report
Lakse
·2022-04-02
👍👍 long way to go but Good for Alzheimer patients
Reply
5
Report
fhho32
·2022-04-01
Ok
Reply
3
Report
Fold Replies
- TraderNeo:
  2022-04-02
  Reply
  Report
BenjiFuji
·2022-04-01
Still a long way to go after phase 1...
Reply
4
Report
Peem
·2022-04-01
Ok
Reply
3
Report
Fold Replies
- Wenikho:
  Ok
  2022-04-02
  Reply
  Report
Justin8991
·2022-04-01
Ok
Reply
3
Report
Wilson Tan
·2022-04-01
Great ariticle, would you like to share it?
Reply
6
Report
claratan
·2022-04-01
Wow
Reply
3
Report
Lulup
·2022-04-01
good
Reply
3
Report
Xxxtaengxx
·2022-04-01
K
Reply
5
Report
Fold Replies
- bryancyh99:
  👍
  2022-04-01
  Reply
  Report
- Xxxtaengxx:
  K
  2022-04-01
  Reply
  Report
NP_YT
·2022-04-01
Good
Reply
4
Report
psion
·2022-04-01
Like and comment pl
Reply
6
Report
Fold Replies
- JeremyKok:
  hi. please like and comment back. thank you.
  2022-04-02
  Reply
  Report
- Justin8991:
  Ok
  2022-04-01
  Reply
  Report
Cool bird
·2022-04-01
yay
Reply
6
Report
Fold Replies
- NP_YT:
  Ok
  2022-04-01
  Reply
  Report
- Cool bird:
  Nice
  2022-04-01
  Reply
  Report
teslaudi
·2022-04-01

Reply
7
Report
Fold Replies
- jakejak3jake:
  Like
  2022-04-01
  Reply
  Report
- teslaudi:
  yes
  2022-04-01
  Reply
  Report
newtoUS
·2022-04-01
Lile
Reply
8
Report
Fold Replies
- Peem:
  ok
  2022-04-01
  Reply
  Report
- Kevin92:
  Like
  2022-04-01
  Reply
  Report
- newtoUS:
  k
  2022-04-01
  Reply
  Report
View more 1 comments
FookChia
·2022-04-01
Like pls
Reply
8
Report
Fold Replies
- JeremyKok:
  hi. please like and comment back. thank you.
  2022-04-02
  Reply
  Report
- Joyus:
  K
  2022-04-01
  Reply
  Report
Taishu1234
·2022-04-01
Hi
Reply
9
Report
Fold Replies
- Ray19:
  Ok
  2022-04-01
  Reply
  Report
- Alvisng:
  Ok
  2022-04-01
  Reply
  Report
- Taishu1234:
  Hi
  2022-04-01
  Reply
  Report

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1126755850?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2022-04-01 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126755850","market":"us","top_or_hot":-1,"title":"Longeveron Shares Jumped Another 10% in Morning Trading","media":"Tiger Newspress","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGVN","symbol_name":"Longeveron Inc","start_time":0,"source_url":"","article_id":"1126755850","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","pubTimestamp":1648820604,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGVN":"Longeveron Inc"},"translate_title":"在早盘交易中，Longeveron的股价又上涨了10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGVN":0.9},"content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[{"id":9016959602,"gmtCreate":1649120478173,"gmtModify":1676534454867,"author":{"id":"4101868132463050","authorId":"4101868132463050","name":"Gneiss","avatar":"https://static.tigerbbs.com/04e6942e7cce10823f5ef0af66f4c932","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4101868132463050","authorIdStr":"4101868132463050"},"htmlText":"Great news!","listText":"Great news!","text":"Great news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016959602","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9018757164,"gmtCreate":1649108006573,"gmtModify":1676534449861,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3565081661382277","authorIdStr":"3565081661382277"},"htmlText":"Ff","listText":"Ff","text":"Ff","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":1,"commentSize":16,"repostSize":0,"link":"https://ttm.financial/post/9018757164","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101064862,"gmtCreate":1649108076653,"gmtModify":1663246195729,"authorId":3565081661382277,"author":{"id":3565081661382277,"idStr":"3565081661382277","authorId":3565081661382277,"name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9018757164,"type":1,"supId":0,"prevId":0,"content":"Pp","text":"Pp","html":"Pp"},{"id":101064868,"gmtCreate":1649108114834,"gmtModify":1663246195651,"authorId":3565081661382277,"author":{"id":3565081661382277,"idStr":"3565081661382277","authorId":3565081661382277,"name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9018757164,"type":1,"supId":0,"prevId":0,"content":"Gf","text":"Gf","html":"Gf"},{"id":101064871,"gmtCreate":1649108140199,"gmtModify":1663246194925,"authorId":3565081661382277,"author":{"id":3565081661382277,"idStr":"3565081661382277","authorId":3565081661382277,"name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9018757164,"type":1,"supId":0,"prevId":0,"content":"Dd","text":"Dd","html":"Dd"},{"id":101064856,"gmtCreate":1649108059175,"gmtModify":1663246194839,"authorId":3565081661382277,"author":{"id":3565081661382277,"idStr":"3565081661382277","authorId":3565081661382277,"name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9018757164,"type":1,"supId":0,"prevId":0,"content":"Dd","text":"Dd","html":"Dd"},{"id":101064869,"gmtCreate":1649108122908,"gmtModify":1663246194242,"authorId":3565081661382277,"author":{"id":3565081661382277,"idStr":"3565081661382277","authorId":3565081661382277,"name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9018757164,"type":1,"supId":0,"prevId":0,"content":"Dr","text":"Dr","html":"Dr"}],"langContent":"EN"},{"id":9011416265,"gmtCreate":1648905793566,"gmtModify":1676534420373,"author":{"id":"3583735307988740","authorId":"3583735307988740","name":"Wenikho","avatar":"https://static.tigerbbs.com/48d673eefef20f75808048d78501a48f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583735307988740","authorIdStr":"3583735307988740"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011416265","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011601666,"gmtCreate":1648858911493,"gmtModify":1676534411328,"author":{"id":"4099488158821640","authorId":"4099488158821640","name":"Lakse","avatar":"https://static.tigerbbs.com/9917c89f79766bda212d6a8e45307c1c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4099488158821640","authorIdStr":"4099488158821640"},"htmlText":"👍👍 long way to go but&nbsp;Good for Alzheimer patients","listText":"👍👍 long way to go but&nbsp;Good for Alzheimer patients","text":"👍👍 long way to go but Good for Alzheimer patients","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011601666","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011121947,"gmtCreate":1648830817419,"gmtModify":1676534407295,"author":{"id":"4100143081992750","authorId":"4100143081992750","name":"fhho32","avatar":"https://community-static.tradeup.com/news/2e9d1fc00d659255c125be74d13236ea","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4100143081992750","authorIdStr":"4100143081992750"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9011121947","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101040927,"gmtCreate":1648877626579,"gmtModify":1648877626579,"authorId":3576119840362689,"author":{"id":3576119840362689,"idStr":"3576119840362689","authorId":3576119840362689,"name":"TraderNeo","avatar":"https://static.tigerbbs.com/85e1a1e44089d2f20240d3e7bc6fc0c7","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.93%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011121947,"type":1,"supId":0,"prevId":0,"content":"[Cool]","text":"[Cool]","html":"[Cool]"}],"langContent":"EN"},{"id":9011113738,"gmtCreate":1648826946268,"gmtModify":1676534406506,"author":{"id":"4110175785559852","authorId":"4110175785559852","name":"BenjiFuji","avatar":"https://community-static.tradeup.com/news/330f59d829009a2c318784ab2b5e6098","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":0,"idStr":"4110175785559852","authorIdStr":"4110175785559852"},"htmlText":"Still a long way to go after phase 1...&nbsp;","listText":"Still a long way to go after phase 1...&nbsp;","text":"Still a long way to go after phase 1...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011113738","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011139309,"gmtCreate":1648825899649,"gmtModify":1676534406082,"author":{"id":"4095593496574550","authorId":"4095593496574550","name":"Peem","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":3,"crmLevelSwitch":1,"idStr":"4095593496574550","authorIdStr":"4095593496574550"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9011139309","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101043252,"gmtCreate":1648905784996,"gmtModify":1663246098148,"authorId":3583735307988740,"author":{"id":3583735307988740,"idStr":"3583735307988740","authorId":3583735307988740,"name":"Wenikho","avatar":"https://static.tigerbbs.com/48d673eefef20f75808048d78501a48f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011139309,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":9011130323,"gmtCreate":1648825847685,"gmtModify":1676534406041,"author":{"id":"3575292984950927","authorId":"3575292984950927","name":"Justin8991","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575292984950927","authorIdStr":"3575292984950927"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011130323","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":619066010,"gmtCreate":1648823559132,"gmtModify":1676532931699,"author":{"id":"3562068205677436","authorId":"3562068205677436","name":"Wilson Tan","avatar":"https://static.tigerbbs.com/afe6f718ebee45a3a69d0fdf01d6fef6","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":1,"idStr":"3562068205677436","authorIdStr":"3562068205677436"},"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/619066010","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9011372989,"gmtCreate":1648823430866,"gmtModify":1676534405463,"author":{"id":"3573731928321338","authorId":"3573731928321338","name":"claratan","avatar":"https://static.tigerbbs.com/9c6bbdac9048ff2e4b740f272576e2be","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3573731928321338","authorIdStr":"3573731928321338"},"htmlText":"Wow&nbsp;","listText":"Wow&nbsp;","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011372989","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011370298,"gmtCreate":1648823015529,"gmtModify":1676534405358,"author":{"id":"3565388060054436","authorId":"3565388060054436","name":"Lulup","avatar":"https://static.tigerbbs.com/5bd91320845c61e8df5d3fb4163d4d92","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3565388060054436","authorIdStr":"3565388060054436"},"htmlText":"good&nbsp;","listText":"good&nbsp;","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011370298","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011347080,"gmtCreate":1648822883962,"gmtModify":1676534405333,"author":{"id":"3586262821219407","authorId":"3586262821219407","name":"Xxxtaengxx","avatar":"https://static.tigerbbs.com/6f931aa4bcd7d456a210e2c84b56950f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586262821219407","authorIdStr":"3586262821219407"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9011347080","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101033788,"gmtCreate":1648823875567,"gmtModify":1663246060047,"authorId":3577660167902155,"author":{"id":3577660167902155,"idStr":"3577660167902155","authorId":3577660167902155,"name":"bryancyh99","avatar":"https://static.tigerbbs.com/753a28c8849ea9234f42c65918153213","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.10","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011347080,"type":1,"supId":101033560,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":101033560,"gmtCreate":1648822896300,"gmtModify":1663246057749,"authorId":3586262821219407,"author":{"id":3586262821219407,"idStr":"3586262821219407","authorId":3586262821219407,"name":"Xxxtaengxx","avatar":"https://static.tigerbbs.com/6f931aa4bcd7d456a210e2c84b56950f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011347080,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"EN"},{"id":9011345253,"gmtCreate":1648822744500,"gmtModify":1676534405299,"author":{"id":"3572043809285615","authorId":"3572043809285615","name":"NP_YT","avatar":"https://static.itradeup.com/news/fad9f70abb174e3e09e4caf3f9c0c13a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3572043809285615","authorIdStr":"3572043809285615"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011345253","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9011343897,"gmtCreate":1648822386447,"gmtModify":1676534405156,"author":{"id":"3581845985051272","authorId":"3581845985051272","name":"psion","avatar":"https://static.tigerbbs.com/ab2eccc9177a2c142fab5a37345bc343","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581845985051272","authorIdStr":"3581845985051272"},"htmlText":"Like and comment pl","listText":"Like and comment pl","text":"Like and comment pl","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9011343897","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101036830,"gmtCreate":1648857705425,"gmtModify":1663246072738,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011343897,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":101034362,"gmtCreate":1648825874515,"gmtModify":1663246060830,"authorId":3575292984950927,"author":{"id":3575292984950927,"idStr":"3575292984950927","authorId":3575292984950927,"name":"Justin8991","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011343897,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":9011349263,"gmtCreate":1648822279184,"gmtModify":1676534405020,"author":{"id":"3576790897131947","authorId":"3576790897131947","name":"Cool bird","avatar":"https://static.tigerbbs.com/2a18793145d8e701bbc80926ad081518","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3576790897131947","authorIdStr":"3576790897131947"},"htmlText":"yay","listText":"yay","text":"yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9011349263","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101033536,"gmtCreate":1648822756451,"gmtModify":1663246057829,"authorId":3572043809285615,"author":{"id":3572043809285615,"idStr":"3572043809285615","authorId":3572043809285615,"name":"NP_YT","avatar":"https://static.itradeup.com/news/fad9f70abb174e3e09e4caf3f9c0c13a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011349263,"type":1,"supId":101033465,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":101033465,"gmtCreate":1648822285073,"gmtModify":1663246054245,"authorId":3576790897131947,"author":{"id":3576790897131947,"idStr":"3576790897131947","authorId":3576790897131947,"name":"Cool bird","avatar":"https://static.tigerbbs.com/2a18793145d8e701bbc80926ad081518","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011349263,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":9011352753,"gmtCreate":1648821845883,"gmtModify":1676534404923,"author":{"id":"4106459081730070","authorId":"4106459081730070","name":"teslaudi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"4106459081730070","authorIdStr":"4106459081730070"},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9011352753","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101033500,"gmtCreate":1648822528471,"gmtModify":1663246057838,"authorId":3581491815672686,"author":{"id":3581491815672686,"idStr":"3581491815672686","authorId":3581491815672686,"name":"jakejak3jake","avatar":"https://static.tigerbbs.com/1881c4ef0863e5796041081ddadee92e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011352753,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"},{"id":101033395,"gmtCreate":1648821855493,"gmtModify":1663246056637,"authorId":4106459081730070,"author":{"id":4106459081730070,"idStr":"4106459081730070","authorId":4106459081730070,"name":"teslaudi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011352753,"type":1,"supId":0,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"}],"langContent":"EN"},{"id":9011322701,"gmtCreate":1648820892299,"gmtModify":1676534404714,"author":{"id":"3575929769091766","authorId":"3575929769091766","name":"newtoUS","avatar":"https://static.tigerbbs.com/9b8dfb089132dd6830b3d50bd9ba1db2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575929769091766","authorIdStr":"3575929769091766"},"htmlText":"Lile","listText":"Lile","text":"Lile","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/9011322701","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101034374,"gmtCreate":1648825905599,"gmtModify":1663246060644,"authorId":4095593496574550,"author":{"id":4095593496574550,"idStr":"4095593496574550","authorId":4095593496574550,"name":"Peem","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.15","exceedPercentage":"60.72%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011322701,"type":1,"supId":101033480,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":101033354,"gmtCreate":1648821522838,"gmtModify":1663246056849,"authorId":3576274545052910,"author":{"id":3576274545052910,"idStr":"3576274545052910","authorId":3576274545052910,"name":"Kevin92","avatar":"https://static.tigerbbs.com/c5ff4addbbdb8d9d15fec29f9709b0c3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011322701,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"},{"id":101033266,"gmtCreate":1648820924539,"gmtModify":1663246056730,"authorId":3575929769091766,"author":{"id":3575929769091766,"idStr":"3575929769091766","authorId":3575929769091766,"name":"newtoUS","avatar":"https://static.tigerbbs.com/9b8dfb089132dd6830b3d50bd9ba1db2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011322701,"type":1,"supId":0,"prevId":0,"content":"k","text":"k","html":"k"},{"id":101033480,"gmtCreate":1648822379877,"gmtModify":1663246054948,"authorId":3581845985051272,"author":{"id":3581845985051272,"idStr":"3581845985051272","authorId":3581845985051272,"name":"psion","avatar":"https://static.tigerbbs.com/ab2eccc9177a2c142fab5a37345bc343","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011322701,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9011328593,"gmtCreate":1648820711197,"gmtModify":1676534404661,"author":{"id":"3582011605223524","authorId":"3582011605223524","name":"FookChia","avatar":"https://static.tigerbbs.com/c8b4a1f99e8c51a51e93bfd003334327","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3582011605223524","authorIdStr":"3582011605223524"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9011328593","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101036836,"gmtCreate":1648857724471,"gmtModify":1663246073827,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011328593,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":101033432,"gmtCreate":1648822087480,"gmtModify":1663246057341,"authorId":3574397806525082,"author":{"id":3574397806525082,"idStr":"3574397806525082","authorId":3574397806525082,"name":"Joyus","avatar":"https://static.tigerbbs.com/be788755f764f5e5e5cb1d49eec190f0","vip":1,"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011328593,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"EN"},{"id":9011328347,"gmtCreate":1648820666675,"gmtModify":1676534404678,"author":{"id":"3586770271918953","authorId":"3586770271918953","name":"Taishu1234","avatar":"https://static.tigerbbs.com/304c84abf6afa2a712e382db070e86df","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586770271918953","authorIdStr":"3586770271918953"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9011328347","repostId":1126755850,"repostType":4,"repost":{"id":"1126755850","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648820604,"share":"https://ttm.financial/m/news/1126755850?lang=&edition=full_marsco","pubTime":"2022-04-01 21:43","market":"us","language":"en","title":"Longeveron Shares Jumped Another 10% in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126755850","media":"Tiger Newspress","summary":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-st","content":"<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron Shares Jumped Another 10% in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron Shares Jumped Another 10% in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-04-01 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.</p><p><img src=\"https://static.tigerbbs.com/e44df14a79c1ec35971eceed38c635d7\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.</p><p>The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.</p><p>Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.</p><p>The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.</p><p>“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.</p><p>In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126755850","content_text":"Longeveron shares jumped another 10% in morning trading. The stock soared 105% yesterday.Clinical-stage biotech announcingthe peer-reviewed publication of results from a Phase 1 trial for its Alzheimer’s disease candidate in Lomecel-B on Thursday.The data were published in the Journal of the Alzheimer’s Association with the title “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” the company said.Lomecel-B, Longeveron’s (LGVN) lead candidate, is a cell-based therapy product derived from the bone marrow of young, healthy adult donors.The 33-patient Phase 1 trial, designed to evaluate its effect in patients with mild Alzheimer’s disease, had previously met the primary endpoint indicating it was well-tolerated among patients.“We are pleased and encouraged by the publication of our study in this high-impact journal,” Chief Executive Geoff Green noted.In January, Longeveron (LGVN) announced the initiation of Phase 2a clinical trial for the candidate in Alzheimer’s.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":101033336,"gmtCreate":1648821403915,"gmtModify":1663246058427,"authorId":3581771143434296,"author":{"id":3581771143434296,"idStr":"3581771143434296","authorId":3581771143434296,"name":"Ray19","avatar":"https://community-static.tradeup.com/news/b009e5dc10330ec9adb81b8620da9d6e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011328347,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":101033240,"gmtCreate":1648820813493,"gmtModify":1663246057842,"authorId":3573785419905679,"author":{"id":3573785419905679,"idStr":"3573785419905679","authorId":3573785419905679,"name":"Alvisng","avatar":"https://static.tigerbbs.com/9c98798dbcc9d108a5dd55ddace59bfd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011328347,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":101033210,"gmtCreate":1648820675858,"gmtModify":1663246056940,"authorId":3586770271918953,"author":{"id":3586770271918953,"idStr":"3586770271918953","authorId":3586770271918953,"name":"Taishu1234","avatar":"https://static.tigerbbs.com/304c84abf6afa2a712e382db070e86df","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9011328347,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":180,"commentSize":19,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}